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Heparan sulfate (HS) is a complex polysaccharide that takes part in most major cellular
processes, through its ability to bind and modulate a very large array of proteins.These inter-
actions involve saccharide domains of specific sulfation pattern (S-domains), the assembly
of which is tightly orchestrated by a highly regulated biosynthesis machinery. Another level
of structural control does also take place at the cell surface, where degrading enzymes
further modify HS post-synthetically. Amongst them are the Sulfs, a family of extracellular
sulfatases (two isoforms in human) that catalyze the specific 6-O-desulfation of HS. By tar-
geting HS functional sulfated domains, Sulfs dramatically alter its ligand binding properties,
thereby modulating a broad range of signaling pathways. Consequently, Sulfs play major
roles during development, as well as in tissue homeostasis and repair. Sulfs have also been
associated with many pathologies including cancer, but despite increasing interest, the role
of Sulfs in tumor development still remains unclear. Studies have been hindered by a poor
understanding of the Sulf enzymatic activities and conflicting data have shown either anti-
oncogenic or tumor-promoting effects of these enzymes, depending on the tumor models
analyzed. These opposite effects clearly illustrate the fine tuning of HS functions by the
Sulfs, and the need to clarify the mechanisms involved. In this review, we will detail the
present knowledge on the structural and functional properties of the Sulfs, with a special
focus on their implication during tumor progression. Finally, we will discuss attempts and
perspectives of using the Sulfs as a biomarker of cancer prognosis and diagnostic and as
a target for anti-cancer therapies.
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INTRODUCTION
In metazoan organisms, coordination of individual cells behavior
is largely determined by the concerted action of two large ensem-
bles of pericellular molecules: the extracellular matrix (ECM),
which provides cells a solid substratum, and small soluble effec-
tor proteins that diffuse within the extracellular milieu and carry
signaling activities (1–3). Once released, these diffusible factors
may bind to specific signaling receptors expressed at the surface
of target cells where they trigger definite biological responses.
Most of these extracellular messengers, which include hundreds
of interleukins, monokines, lymphokines, chemokines, growth
factors, morphogens, . . ., etc. (and will be collectively referred
here as cytokines), are endowed with pleiotropic and overlapping
activities. They can be secreted by many distinct cell types, their
cognate receptors are widely distributed within tissues, and they
are usually effective at very low concentrations (nano- to picomo-
lar range). However, their activities are not systemic and, except
during pathological conditions, their functions are strictly focused
and highly regulated in time and space (4). For that purpose, regu-
lation of signaling events carried out by diffusible ligands also takes
place upstream of the ligand-receptor interaction itself, through
processes in which the ECM plays a central role. It has been indeed
widely appreciated that the ECM, through which soluble factors
diffuse, does not just ensure tissue cohesiveness but by immobi-
lizing many of the above mentioned soluble cytokines provides
a structural basis to control their activity. Mechanistically, this
sequestration changes their availability, stability, structure, and
reactivity, and could lead to specific processing. This provides cells
with a system to control and regulate, in their close surround-
ing, the information carried out by soluble factors (5, 6). It is
therefore perhaps not surprising that these soluble and insolu-
ble systems are strongly connected and work together to regulate
cellular communication, as the former makes possible the trans-
fer of information between distant cells, while the latter provides
a scaffold for multicellularity (7). Amongst ECM components,
proteoglycans (PGs) represent one of the major classes of mol-
ecules that immobilize and control cytokines (2, 3, 8, 9). PGs
bind a variety of growth factors and matrix molecules which
play crucial roles in cancer cell-stroma communications (10).
The binding of soluble factors to PGs generates reservoirs and
gradients and, in promoting ligands receptor recognition, ampli-
fies signaling. In that context, the purpose of this review is to
discuss how Sulfs, a recently discovered enzyme family modify-
ing PG structure, take part to the complex relationships between
cells and their close surroundings, with a special focus on tumor
development.
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PROTEOGLYCANS AND GLYCOSAMINOGLYCANS
Proteoglycans constitute a group of some 30 heterogeneous gly-
coproteins that are substituted with specific polysaccharides of
the glycosaminoglycan (GAG) family (11). GAGs are anionic and
linear polysaccharides, which are ubiquitously present within the
ECM and at the surface of virtually all cells. They comprise
hyaluronan (which does not occur as a PG but in free form)
chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate
(HS), and heparin. Whereas the core protein usually determines
the localization of the molecule, the attached GAG chains, and
in particular those of the HS type, are predominantly involved
in protein recognition (12, 13). HS binds hundreds of protein lig-
ands, including cytokines (as defined above) but also adhesion and
matrix molecules, receptors, enzymes, plasma proteins, etc. These
interactions serve a large number of purposes and functionally,
HS has been known to affect the local concentration, the com-
partmentalization, the stability, the structure, and/or the activity
of its binding partners. Protein-HS interactions thus play critical
roles in a very large number of biological systems, for example, in
mediating the formation of chemokine gradients along which cells
can migrate directionally (14, 15), in providing a template to jux-
tapose two proteins such as growth factor-receptor complexes to
facilitate signal transduction (16), in protecting cytokines against
proteolysis, in inducing protein conformational changes (17), in
providing reservoirs of active factors that can be mobilized in spe-
cific conditions, or in generating local concentrations of a given
binding protein by controlling its diffusion (18) thereby generating
local concentrations of a given protein. In particular, as mentioned
above, many of the proteins that direct cellular proliferation, such
as FGFs (19) and TGF (20), cellular migration, and metastasis such
as CXCL12 (21), or control angiogenesis, including VEGF, endo-
statin, or TG2 (22), are all regulated upon binding to HS in the
pericellular milieu.
From a structural view, the multiple binding activities of HS
are closely related to its extended structural variability. The chain
is synthesized in the Golgi apparatus by enzymes that initially
polymerize alternating glucuronic acid (GlcA) and N -acetyl-
glucosamine (GlcNAc). The resulting disaccharide repeats are then
variously modified by interdependent reactions that do not occur
uniformly along the chain. The N -deacetylase/sulfotransferases
NDSTs first catalyze the N-deacetylation, usually followed by
the N-sulfation of the GlcNAc units. Remarkably, this occurs
in restricted domains of usually 3–6 disaccharides (known as S-
domains) in which the GlcA can be C5-epimerized into iduronic
acid (IdoA), followed by various O-sulfations, frequently at the
C6 and C2 position of the GlcN and IdoA respectively, and more
rarely at the C3 and C2 positions of the GlcN and GlcA respec-
tively. Variations in the degree of epimerization and sulfation
patterning generate a very large polydispersity and, as such, pro-
vide HS chains with distinct docking sites for the various ligands
of the polysaccharide (23). Protein binding properties are there-
fore largely dependent on the degree and pattern of HS sulfation,
which are dynamically regulated at the level of tissue and cell type,
as well as during development and pathological conditions such as
tumor progression. The 6-O-sulfation of HS, for instance, has been
shown to be important for binding/activation of many signaling
molecules involved in cell proliferation, adhesion, and migration.
These include FGFs such as FGF1, FGF4, FGF7 and FGF10 (24–
28), HGF (26, 29), VEGF (30), PDGF (31), fibronectin (32), and
chemokines such as CXCL12 (33). Furthermore, in the case of
FGF2, although 6-O-sulfates are not necessary for binding, they
are required for promoting the growth factor activity (34–36).
Expectedly, a number of reports have associated increased levels
of 6-O-sulfation with tumor progression, highlighting HS biosyn-
thesis 6-O-sulfotransferases (6OSTs) as attractive targets for anti-
cancer and anti-angiogenic therapies (37, 38). In mammals, three
6OST isoforms have been identified (39). However, these enzymes
showed very little differences in substrate specificity, which did
not suggest a tight control of HS 6-O-sulfation status during its
biosynthesis (40).
SULFS: EXTRACELLULAR SULFATASES REGULATING HS
STRUCTURE AND FUNCTION
The assembly of specific saccharide motifs involved in protein
binding/recognition was originally thought to rely exclusively on
the complex and highly regulated HS biosynthesis machinery. The
field took a dramatic turn, when Dhoot and colleagues identified
in quail a new extracellular sulfatase, QSulf-1, that positively regu-
lated Wnt signaling through desulfation of HSPGs (41). Orthologs
have since been identified in human, mouse, rat, chicken, zebra
fish,Drosophila,Xenopus, and C. elegans, as well as two isoforms of
the enzyme, Sulf-1 and -2 (42–45). Sulfs were shown to be endo-
sulfatases that catalyzed selective removal of 6-O-sulfate groups
from internal S-domains in cell surface and ECM HS and rapidly
emerged as critical regulators of key functions of the polysaccha-
ride in physiological processes such as embryogenesis and tissue
regeneration, and in diseases such as cancer.
Sulfs markedly distinguish from other members of the sulfa-
tase family. Sulfatases are structurally and mechanistically highly
conserved enzymes in eukaryotic and prokaryotic species (46).
They are intracellular enzymes involved in the catabolism of
sulfated compounds and exert their exosulfatase activity in
acidic conditions of lysosomal compartments. Their catalytic
domain comprises a unique post-translational modification, an α-
formylglycine (FGly) residue resulting from oxidation of a strictly
conserved cysteine, which is essential for enzyme activity (47).
Many members of the sulfatase family are able to cleave sulfate
ester from small aryl compounds such as 4-methylumbelliferyl
sulfate (4-MUS), and are thus referred to as arylsulfatases (46). In
contrast, Sulfs are extracellular enzymes that exert an endosulfa-
tase activity at neutral pH and display poor sequence homology
with other sulfatases. Sulf-1 and -2 are very similar in length (870–
875 amino acids, depending on species) and are characterized by
a unique structural organization. Based on sequence homology,
Sulfs consist of four primary domains: a cleavable signal sequence,
a catalytic domain (CAT), a central hydrophilic domain (HD), and
a C-terminal region (C-ter) (44, 48, 49).
The Sulf CAT domain is highly homologous to the conserved
catalytic domains of all eukaryotic sulfatases. It contains the post-
translationally modified FGly residue that directly participates in
the hydrolytic cleavage reaction of sulfate esters at neutral pH (46,
50). In contrast, the HD domain is a unique feature of the Sulfs and
shows no homology with any other protein sequences. It is par-
ticularly rich in basic amino acids, including a C-terminal cluster
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of 12 consecutive basic amino acids, and represents by itself 40%
of Sulf overall charge (27% basic and 13% acid). The HD domain
is not required for the enzyme arylsulfatase activity and hydrol-
ysis of small substrates, such as 4-MUS. However, it is essential
for recognition and endosulfatase activity on HS, and for cell sur-
face localization of the Sulfs (48, 49). Finally, the C-ter domain
displays significant homology with the C-ter region of lysosomal
glucosamine-6-sulfatase (G6S). It has been suggested that C-ter
regions of Sulfs and G6S confer specificity toward glucosamine
(44). The mature Sulf consists of a disulfide-linked heterodimer
of 75 and 50 kDa subunits, which is formed through processing of
a 125-kDa pro-protein by furin-type proteases (49, 51). There are
two putative furin-type proteinase cleavage sites in Human Sulf
isoforms HSulf-1 and -2. Blocking the cleavage by mutating both
sites had no effect on secretion, aryl sulfatase activity, and solubil-
ity of Sulfs but inhibited their ability to potentiate Wnt signaling
(49). Interestingly, other studies showed that deletion or mutation
of furin cleavage sites had no effect on the enzyme endosulfatase
activity, or ability to inhibit FGF signaling (48, 51). Finally, Sulfs are
glycosylated proteins, with 10–11 putative N-glycosylation sites,
mainly located within the N-terminal half of the enzyme (44). Gly-
cosylation inhibitor studies revealed that glycosylation of QSulf-1
is essential for its enzymatic activity, membrane targeting, and
secretion (52). However, the role of glycosylation in human Sulfs
has not been investigated yet.
The substrate specificity of the Sulfs remains unclear. However,
in vivo and in vitro data indicate that these enzymes essentially
exert their 6-O-sulfatase activity on (UA2S-GlcNS6S) trisulfated
disaccharides units, which are found within HS S-domains, and
to a much lesser extent on (UA-GlcNS6S) disulfated disaccharides
(53–57). No effect on other 6-O-sulfated disaccharides could be
observed, suggesting a requirement for N -sulfate groups. In con-
trast, the nature of the uronate (either glucuronic or IdoA) does
not seem to be critical for Sulf activity. For QSulfs, 6-O-desulfation
was reported on GlcA- but not IdoA-containing disulfated disac-
charides (53), but HSulf-2 showed similar activity on both these
disaccharides (58). QSulf-1 and -2 have shown similar substrate
specificity and redundant HS remodeling functions (53, 57). For
mammalian Sulfs, further information about enzyme specificity
has been obtained from studying knock-out mice (54, 59–65).
Sulf-1 or -2 single knock-out mice showed normal viability and no
phenotypic and histological defects, suggesting overlapping func-
tions of the two isoforms and compensation effects. In contrast,
Sulf-1/2 double deficient mice suffered multiple developmental
abnormalities and high neonatal mortality. Structural analyses
of HS from mSulf-1−/− fibroblasts showed elevated levels of
all 6-O-sulfated disaccharides compared with the wild-type HS.
For mSulf-2−/− HS, 6-O-sulfation increase was mainly observed
within HS non-sulfated and transition zones (54), indicating that
the enzyme may also act outside HS S-domains. These data there-
fore indicate that, unlike their avian orthologs, mammalian Sulf
activity may not be restricted to HS highly sulfated S-domains,
and that Sulf-1 and -2 isoforms may have different effects on
HS sulfation pattern. In agreement with this, another study on
Sulf knock-out mice recently suggested that Sulf-1 and -2 iso-
forms differentially contributed to the generation of organ-specific
sulfation patterns of HS (66).
The mechanisms by which these enzymes catalyze HS desulfa-
tion is poorly understood. The CAT domain, comprising the FGly
residue, is able to hydrolyze the general arysulfatase substrate 4-
MUS (Km of ≈10 mM). Because of the close homology of this
domain with arylsulfatase A, B (ARS-A; ARS-B), and G6S, it is
thought that Sulfs share a similar desulfation mechanism. In ARS-
A, hydroxylation of the FGly residue by a water molecule forming
the activated hydroxyl formylglycine (a formylglycine hydrate) is
a necessary step for the enzyme’s sulfatase activity (46). One of
the two oxygens of the aldehyde hydrate attacks the sulfur of the
sulfate ester, leading to a transesterification of the sulfate group
onto the aldehyde hydrate. Simultaneously, the substrate alcohol
is released. The released sulfate is eliminated from the enzyme-
sulfate intermediate by an intramolecular rearrangement. The
“intramolecular hydrolysis”allows the aldehyde group to be regen-
erated. The active site of ARS-A comprises nine conserved residues
that are found to be critical for catalytic activity (67). Based on this
information, site-directed mutagenesis should help in understand-
ing whether Sulf-1 and -2 share the same enzymatic mechanism
as lysosomal sulfatases. In contrast, the 6-O-desulfation of HS
natural substrate requires the presence of the HD domain (48,
49). In a recent study, we have investigated the mechanism by
which HSulfs affect S-domain sulfation pattern, using a highly
sulfated heparin octasaccharide as a mimic of HS functional S-
domains (55). Analyses including mass spectrometry, NMR, and
HS oligosaccharide sequencing revealed that HSulfs catalyze the
6-O-desulfation of HS by a non-random, processive, and ori-
ented mechanism, starting from the non-reducing end of the
oligosaccharide and progressing throughout the whole polysac-
charide toward it reducing end. In addition, we demonstrated that
alteration of 6-O-sulfation pattern directed by such mechanism
enabled differential regulation of FGF-1 and -2 ligands. From
these observations, we proposed a model, in which HSulf CAT
domain exerts a non-specific arylsufatase activity, while the HD
domain is responsible for substrate specificity and binding, and
directs HS processive desulfation (Figure 1). The HD domains of
HSulf-1 and -2 display poor sequence identity (44). Differences in
activity and ligand binding properties of the two isoforms could
therefore result from specific features of their HD domains. This
model suggests that HSulf HD domain plays a major role in the
enzyme activity and specificity and highlights the need of inves-
tigating further its interaction with HS. In this regard, Milz et al.
very recently showed that the HD domain indeed conferred HSulf
specificity toward 6-O-sulfates and that it comprises at least two
distinct HS-binding sites that allow for dynamic interaction with
the polysaccharide (68).
MULTIFACETED ACTIVITIES OF THE SULFS
A MECHANISTIC VIEW: SULFS AS MODULATORS OF GROWTH FACTOR
SIGNALING
As discussed above, 6-O-sulfates are critical for many biological
properties of HS. Through their ability to edit 6-O-sulfation sta-
tus at the level of HS functional S-domains, Sulfs thus constitute a
unique regulatory switch to control ligand binding/activation and
subsequent cellular signaling events. As expected, treatment of
heparin with Sulfs dramatically reduces its ability to bind a num-
ber of protein ligands, including VEGF, FGF1, and chemokines
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FIGURE 1 | Model for HSulf processive activity and differential regulation
of HS ligand binding properties. (A) HSulf hydrophilic domain (HD)
preferentially recognizes and binds to 6-O-sulfates harbored by trisulfated
disaccharides found within HS S-domains (S-dom.), the catalytic site (CAT-D)
of the enzyme being positioned on the most upstream 6-O-sulfate residue
(B). After desulfation, the enzyme progresses along the polysaccharide chain
to accommodate other 6-O-sulfate groups (C). Once the S-domain reducing
end is reached, the absence of appropriate 6-O-sulfates (those present on the
flanking regions (Flank.), or the NAc domains (NAc-dom.) are poor substrates
for the enzyme) downstream CAT-D results in a strong decrease in the affinity
of the enzyme HD for the polysaccharide and the dissociation of the complex
(D). Partial and orientated 6-O-desulfation of S-domains may differentially alter
HS ligand binding (E). From Seffouh et al. (55), copyright by the Federation of
American Societies for Experimental Biology.
SDF/CXCL12 and SLC in an ELISA assay (69). However and most
interestingly, Sulf catalyzed alterations of HS structure cannot
simply be associated with loss of function (Figure 2; Table 1).
Rather, these will induce some signaling pathways and inhibit
others, depending on the isoform involved (Sulf-1 or -2), the pro-
tein ligands targeted, and the biological context. As such, QSulf-1
was originally identified for its ability to promote Wnt signaling
(41, 53). Indeed, although HS is required for Wnt activity, high
affinity interaction with the polysaccharide prevents its binding
to the Frizzled (Fz) receptor and subsequent signaling. QSulf-
1 induced remodeling of HS 6-O-sulfation pattern reduced its
affinity for Wnt, enabling formation of a HS/Wnt/Fz functional
complex (53). A similar mechanism was reported for the activation
of GDNF by Sulf-1 and -2 during mouse neuronal development
(59) and maintenance of spermatogonial stem cells (63). Sulfs
also enhance BMP signaling by modulating its inhibitor Noggin
(57, 70), but on the contrary downregulate FGF1, FGF2, HGF, HB-
EGF,VEGF, amphiregulin, and TGFβ signaling (55, 71–76). Finally,
Sulf-1 has been shown to either enhance or repress Sonic Hedge-
hog (Shh) signaling during neuronal development or in gastric
cancer, respectively (77, 78).
A FUNCTIONAL VIEW: ROLE OF THE SULFS DURING DEVELOPMENT
Insights into the physiological functions of the Sulfs have been
obtained from the study of knock-out organisms, which high-
lighted broad and most probably overlapping functions during
development. As discussed above, only mSulf-1/2 double knock-
out mice display marked phenotypic flaws, which include a variety
of renal, lung, skeletal, and neuronal defects (59–61, 64). Amongst
these, it is worth noting that bone skeletal defects observed in
the Sulf-1−/−/Sulf-2−/− embryos show similarities with those
reported previously in Hs2st-deficient mice,but also EphrinB1 and
BMP-deficient mice and FGFR-1 or -3 hypermorphic mice (60).
This phenotype convergence supports further a role of the Sulfs in
the regulation of BMP, FGF, and/or Ephrin signaling during sternal
development. Neuronal development defects in mSulf knockout
mice included neuroanatomical abnormalities and impaired neu-
rite outgrowth, suggesting non-redundant functions of these two
enzymes during the development of the nervous system (61). Dur-
ing embryogenesis, Sulfs also promote esophageal innervation, by
enhancing GDNF-mediated neurite sprouting (59), and Sulf-1 is
involved in the series of events inducing the switch of ventral
neural progenitor cells toward an oligodendroglial fate, by mod-
ulating Shh distribution and signaling on apical neuroepithelial
cells (77). Finally, Sulfs may also play an important role in carti-
lage formation. In quail, the highest expression level of QSulf-1
was observed in condensing mesenchyme, during the early differ-
entiation stage of chondrogenesis. Interestingly, overexpression of
QSulf-1 in quail micromass cultures enhanced differentiation of
prechondrocytes into chondrogenic lineage, supporting its role in
mesenchymal condensation and early differentiation of cartilagi-
nous elements (65). In rat embryos, in situ hybridization showed a
strong expression of Sulf-1 in the floor plate, choroid plexus, and
cartilage (45).
ROLE OF THE SULFS IN TISSUE HOMEOSTASIS AND REPAIR
Besides their role during development, Sulfs have been shown to
play various functions in homeostasis and repair of various tissues
and organs. Sulfs are involved in muscle regeneration, by promot-
ing satellite cells myogenic differentiation through disruption of
FGF2 (80). Through their ability to modulate GDNF, Sulfs play a
critical role in the maintenance of the spermatogonial stem cells
(63). Sulf-2 has been shown to promote liver regeneration after
partial hepatectomy, by modulating WNT3a and GLI1 signaling
(81). Sulfs take part in cartilage homeostasis, by acting simultane-
ously as a positive and negative regulator of BMP and FGF activity,
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FIGURE 2 | Regulation of HS ligand binding/activating properties
by the Sulfs. (A) High affinity binding of Wnt to 6-O-sulfated HS (HS
chains shown as plain red lines) prevents interaction to its cell surface
receptor Frizzled (Fz). Removal of 6-O-sulfates by the Sulfs (HS chains
shown as dashed red lines) lowers HS/Wnt affinity, enabling binding of
Wnt to Fz and subsequent signaling (red thunderbolt). (B) Formation of
the functional FGF/FGF receptor (FGFR)/HS ternary complex requires
6-O-sulfates. Sulf catalyzed 6-O-desulfation of HS does affect FGF2
binding to HS, but prevents formation of the signaling complex.
(C) Chemokines/HS interaction is critical for the formation of
chemotactic gradients. By inhibiting the interaction of HS with a number
of these chemokines, Sulfs may destabilize such gradients. (D) Noggin
binds with high affinity to 6-O-sulfated HS and sequesters BMP. Upon
Sulf action, the release of Noggin from the cell surface prevents
efficient inhibition of BMP, which can bind to its cognate receptor BMPR
and induce signaling.
Table 1 | Modulation of HS ligand binding/activating properties by the Sulfs.
Ligand Function Effects of Sulfs Reference
Binding Activity
Wnt Embryonic development, cancer ↓ ↑ Ai et al. (53), Dhoot et al. (41)
GDNF Neuronal cell protection/regeneration, spermatogenesis ↓ ↑ Ai et al. (59), Langsdorf et al. (63)
BMP Bone/cartilage morphogenesis ↑ Otsuki et al. (70), Viviano et al. (57)
FGF1 Angiogenesis, wound healing, Embryonic development, cancer ↓ ↓ Seffouh et al. (55), Uchimura et al. (69)
FGF2 Angiogenesis, wound healing, Embryonic development, cancer ↓ Dai et al. (71), Frese et al. (48), Lai et al. (72), Li
et al. (74), Narita et al. (75)
HGF Angiogenesis, tissue regeneration, cancer ↓ Lai et al. (73), Narita et al. (75)
HB-EGF Angiogenesis, wound healing, cancer ↓ Dai et al. (71), Lai et al. (72)
SDF/CXCL12 Chemotaxis, cancer ↓ Uchimura et al. (69)
VEGF Angiogenesis, cancer ↓ ↓ Narita et al. (75), Uchimura et al. (69)
Amphiregulin Tissue morphogenesis, cancer ↓ Narita et al. (79)
TGFβ Tissue regeneration, embryonic development, regulation of the
immune system, cancer
↓ Yue et al. (76)
Shh Embryonic development, axonal guidance, cancer ↑↓ Danesin et al. (77), Ma et al. (78)
respectively (70). Interestingly, both Sulf-1 and -2 also showed
enhanced expression in osteoarthritic and aging cartilage (82). In
such tissues, resulting changes in HS sulfation pattern may alter
its ability to modulate a variety of growth factors (FGF2, Wnt,
BMP, Noggin), thereby contributing to abnormal chondrocyte
activation and cartilage degradation (82). A study in quail also
suggested a role in vascular homeostasis. Indeed, overexpression
of QSulf-1 decreased adhesion, and increased proliferation and
apoptosis of vascular smooth muscle cells, suggesting that optimal
levels of HS 6-O-sulfation are critical to maintain proper functions
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of these cells (83). In addition, tuning of Sulf-1 expression has
been proposed as a regulatory mechanism of leukocyte infiltration,
by inhibiting binding of L-selectin and monocyte chemoattrac-
tant protein-1 (MCP-1) to vascular basement membrane HSPGs
(84). Lastly, Kalus and colleagues provided evidence that the role
of Sulfs in the nervous system extends beyond development, as
these enzymes promote neuronal and behavioral plasticity in
adults (61).
SULFS AND DISEASES
Aside their multiple physiological functions, Sulfs have also been
involved in a number of pathologies. Amongst these, the role of
Sulfs in cancer has been by far the most studied and will be detailed
below. In addition, overexpression of Sulf-2 has been observed in a
murine model of Type 2 diabetes mellitus (85). Most interestingly,
inhibition of the enzyme reduced post-prandial hypertriglyc-
eridemia and restored VLDL-binding capacity of hepatocytes, thus
highlighting Sulf-2 as an attractive therapeutic target to improve
metabolic dyslipidemia (85). Recently, Sulf-2 overexpression has
also been associated with idiopathic pulmonary fibrosis (IPF),
most likely through the regulation of TGFβ1 signaling in Type
2 alveolar epithelial cells (86).
SULFS IN CANCER: INTRIGUING AND AMBIVALENT
FUNCTIONS
A wealth of evidence has reported that cell transformation and evo-
lution through the different stages of malignancy is accompanied
by modifications in HS expression and structure including changes
in 6-O-sulfation (37, 38, 87). Therefore, when Sulfs emerged as a
new way of post-synthetic editing HS 6-O-sulfation status, poten-
tial roles, and implication in cancer were extensively investigated.
Very early, the down-regulation of HSulf-1 was reported in
ovarian cancer (72). Interestingly, re-expression of HSulf-1 in
ovarian cancer cell lines reduced FGF2/HB-EGF signaling and cell
proliferation in vitro, and increased sensitivity to pro-apoptotic
drugs (72). Lowered levels of HSulf-1 expression were also
observed in hepatocellular carcinoma (HCC), specific subtypes
of breast cancer, clear cell sarcoma, kidney, gastric, and blad-
der cancers (72, 73, 88, 89), but other studies have since shown
that HSulf-1 down-regulation is not ubiquitous in cancer. Orig-
inal data from Lai et al. (72) have been disputed by Backen and
colleagues, who reported a higher HSulf-1 expression in ovarian
tumor cells than in normal cells (90), and overexpression of HSulf-
1 has been broadly observed in cancers including leukemia, head
and neck tumors, gastric and pancreatic cancers, brain tumors,
invasive breast carcinoma and colon, pancreatic, esophageal, and
lung adenocarcinoma (89, 91–94). In contrast, Sulf-2 has been
consistently found over-expressed in tumors (89, 92, 94, 95).
Despite being closely related enzymes, misregulation of Sulf-1
and -2 have strikingly different consequences in cancer (89, 96,
97). Sulf-1 is largely reported as having a tumor suppressor activ-
ity, as described in HCC, myeloma, head and neck, breast, and
pancreatic cancers (71, 73–75, 79, 98). Furthermore, it has been
shown that expression of HSulf-1 in HCC and ovarian cancer cells
enhanced the anti-tumor effects of pro-apoptotic drugs (72, 99,
100). On the contrary, Sulf-2 displays pro-oncogenic activity in
HCC, pancreatic, breast, and lung cancers (94, 95, 97, 101, 102).
Interestingly, silencing Sulf-2 expression in lung carcinoma cells
resulted in loss of the transformed phenotype (102). In clinical
surveys on multiple myeloma and HCC patients, Sulf-2 expres-
sion has been correlated with poor prognosis (91, 101). Finally, a
role of Sulf-2 in the development of drug resistance was suggested
on chronic lymphocytic leukemia cells (103). However, this gen-
eral concept of two Sulfs with clear cut pro- and anti-oncogenic
antagonist activities has been challenged in a number of recent
studies. Overexpression of Sulf-2 has been shown to inhibit growth
of myeloma tumors and breast cancer xenografts (71, 104), and
Sulf-1 has been associated with poor prognosis in gastric cancer
and lung adenocarcinoma (91, 92). Altogether, these conflicting
data clearly highlight our poor understanding of the complex and
multifactorial implication of the Sulfs in cancer.
One explanation may be that most studies on Sulfs were carried
out on established cancer cell lines. Sulf action may thus differ in
the context of clinical tumors,where distinct expression patterns of
these enzymes within tumors could restrict their action to specific
components of the tumor and its microenvironment. Further-
more, since Sulfs are extracellular enzymes, the paracrine activities
of Sulfs expressed by other cell types of the tumor stroma and/or
vasculature may also play a significant role. Regarding expression
of the Sulfs, it is worth noting that in Quail, alternative splic-
ing of QSulf-1 has been shown to generate a shorter isoform,
QSulf-1B (105). Interestingly, full length QSulf-1 and QSulf-1B
displayed antagonist activities, the latter inhibiting Wnt signaling
and promoting angiogenesis. Although such splice variant has not
yet been described for either human isoforms, the balance between
their expression could further contribute to the diversity of Sulf
function during cancer development.
Yet, much work is needed to clarify discrepancies between
in vitro and in vivo observations and understand how two enzymes
with highly similar catalytic activities can have opposite effects in
tumor development. For example, Both HSulfs inhibits signaling
of a number of growth factors in vitro, but display antagonist activ-
ities with regards to proliferation and angiogenesis in vivo (48, 55,
69, 73, 95, 98, 101). One obvious possibility is the existence of dis-
tinct substrate specificities. It is considered that processing of HS
by the Sulfs results in a ~5–7% reduction in sulfate content. As dis-
cussed above, such discrete structural alterations have nonetheless
great functional consequences. Therefore, even subtle variations
in HSulf-1 or -2 specificities may be significant. Both HSulf-1
and -2 have been shown to act on HS [UA(2S)-GlcNS(6S)] and
[UA-GlcNS(6S)] disaccharides, but the 6-O-desulfation of these
disaccharide species is rarely exhaustive (48, 55, 56, 62). HS struc-
tural features could therefore be involved in selective recognition
of the Sulfs, thereby influencing their action along the polysaccha-
ride chain. As discussed above, there is no evidence yet suggesting
differences in substrate recognition for the Sulfs. However, further
investigation would be needed to clarify this particularly complex
issue.
Another attractive hypothesis to explain such discrepancies is
that Sulfs may exert their activity on spatially distinct substrates.
Selective desulfation of cell surface HS would indeed result in
a reduction of growth factor binding/activation and subsequent
tyrosine kinase signaling, while desulfation of matrix HS may
elicit release of growth factors from extracellular storage, thereby
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increasing their bioavailability for cell surface signaling receptors.
In this context, the ability of the enzyme to diffuse throughout
tissues might be a determinant factor: limited diffusion would
restrict the enzyme to an autocrine activity at the cell surface, while
rapid diffusion may allow access to more distant HS moieties,
such as those having a storage function in the ECM. Sulf diffu-
sion/bioavailability may be either controlled by the enzyme levels
of expression, activity rates (efficient desulfation would speed up
the bioavailability of the enzyme toward more distant substrates),
HS-binding properties (residual binding to 6-O-desulfated HS
might slow down the release of the enzyme), or binding to other
cell surface/ECM components. A number of recent observations
provide interesting but incomplete information regarding these
hypotheses. Firstly, a study on HCC patients recently suggested a
bimodal action of Sulf-1, related to its level of expression (97).
Patients with tumors expressing intermediate levels of HSulf-1
showed better survival that those with low or high HSulf-1 expres-
sion. It could be speculated that a low amount of Sulf-1 is not
sufficient for tumor suppressor activity through inhibition of pro-
oncogenic and pro-angiogenic growth factor signaling, but that
too high an expression causes additional alteration of ECM HS.
Secondly, we have recently shown that, although HSulf-1 and
-2 share a similar processive desulfation mechanism, they are
characterized by distinct activity rates (55). Surprisingly, HSulf-
1 displayed the highest activity. However, this analysis was carried
out using a fully sulfated heparin oligosaccharide, and activity
of HSulfs might be different in HS, where clusters of contiguous
trisulfated disaccharides may be a rare occurrence. Thirdly, Frese
and colleagues reported that HSulf-1 binding to 6-O-desulfated
HS was dramatically decreased (48), thereby providing the basis
for the release of the enzyme from its processed substrate. Fur-
ther investigation will be needed to determine whether residual
binding could still influence HSulf-1 diffusion, and whether this
applies similarly for HSulf-2. Lastly, Milz et al. suggested that
HSulf-1 could bind to CS/DS (68). As these GAGs are not suitable
substrates for the enzyme, this interaction may limit diffusion of
HSulf-1 throughout tissues.
Finally, it has been reported that Sulf activity influenced expres-
sion of other GAG related genes, thereby modifying GAG expres-
sion and structure. HSulf-2 has been shown to induce Glypican-3
expression (101). Moreover, differential expression of HS 2-O-
and 6OSTs was reported in Sulf-1/2 knock-out mice, which corre-
lated with variations in HS composition for Sulf non-substrateN -,
2-O-, and 6-O-sulfate groups (62). This observation suggests that
Sulfs can modulate HS structure either directly, through their cat-
alytic activity, or indirectly, by taking part in a feed-back regulatory
mechanism of the polysaccharide biosynthesis.
SULFS AS TARGETS FOR ANTI-CANCER THERAPEUTIC
APPROACHES
HSulfs, and particularly HSulf-2, undoubtedly appear as attractive
targets in cancer therapy. Sulf-2 overexpression and pro-oncogenic
activity have been demonstrated for a number of tumors, including
cancer of poor prognosis such as lung squamous cell carcinoma
and lung adenocarcinoma (102). Sulf-2 therefore represents an
interesting candidate as diagnostic and prognostic biomarkers,
which are greatly needed, in particular for these cancers. Detection
of HSulf-2 as a prognosis marker has already been achieved by
monitoring gene expression or by immunochemistry (91, 93, 101).
However, being extracellular enzymes, an interesting perspective
would be the development of diagnostic/prognostic kits based on
enzymatic assays performed on body fluids of patients, where the
enzyme may accumulate.
Another advantage of HSulf-2 extracellular localization is that
it can easily be targeted by low molecular weight compounds.
Very recently, molecules in clinical development have shown Sulf-
inhibiting activities. A disulfonyl nitrone derivative termed OKN-
007 has been found to inhibit HSulf-2 and tumor growth in HCC
(106). Interestingly, OKN-007 displays anti-glioma properties in a
clinically relevant rat model (107) and safety data are already avail-
able for this molecule, which had previously undergone clinical
trials as a treatment for ischemic stroke (106). In addition, protea-
somal inhibitors have been found to suppress HSulf-2 expression
in a number of cancer cell lines (96). These include FDA/EMEA
approved drug Velcade (bortezomib), which was also shown to
reduce tumor size, in MCF-10 derived mouse xenografts (96).
However, mechanisms by which these compounds inhibit HSulf-2
are unknown and further investigation will be needed to establish
the specificity of this activity.
A more rational approach to increase drug specificity is to
develop HS mimetic inhibitors. The chemically sulfated polysac-
charide PI-88 originally developed as an anti-heparanase agent
has been found to also inhibit Sulfs (108). With regards to these
activities, PI-88 has been tested in clinical trials for the treatment of
lung and prostate cancer, but displays severe side effects (including
immune-induced thrombocytopenia) because of its broad range
of activities (109). Sulfamate-based compounds, notably aryl
sulfamates, have been previously shown to inhibit a broad spec-
trum of bacterial and eukaryotic sulfatases (46). With this regard,
Schelwies and colleagues recently designed sulfatase inhibitors cor-
responding to glucosamine-6-sulfamate analogs, which showed
selectivity toward HSulfs (110). An interesting perspective pointed
out by the authors would be to include such glucosamine mimetics
within specific HS saccharide epitopes, in order to selectively target
some signaling pathways. Finally, the development of monoclonal
antibodies raised against HSulf-2 could lead to antibody-based
therapies (93). Altogether, these data clearly emphasize the need
of increasing specificity of drug candidates toward Sulf. Further-
more, with regards of the opposing activities of Sulf-1 and -2 in
the development of many cancers, it could be of high interest
to design inhibitors discriminating these two isoforms. How-
ever as discussed above, this would require further insights into
the mechanism of action of these enzymes. Obtaining structural
data on the Sulfs is another scientific achievement that would
undoubtedly deliver crucial information for the development of
biologically active inhibitory compounds. Structures of human
sulfatases ArsA, ArsB, and ArsC have been solved by X-ray crystal-
lography (111–113). However, solving the structure of the Sulfs,
and in particular of their HD domains, may prove extremely com-
plex, as these domains display no homology with any known
proteins, are reported as poorly structured from in silico amino
acid sequence analysis, and are particularly rich in (most proba-
bly) surface exposed charged amino acids, suggesting high protein
flexibility.
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CONCLUSION
Tumor progression and metastasis are underpinned by mecha-
nisms involving cell growth, dissociation, and migration, base-
ment membrane degradation, invasion into the adjacent ECM,
adhesion to the vasculature and extravasation/proliferation into
metastatic sites. These are both cell- and tissue-driven processes
that requires a vast arrays of information and molecular sys-
tems including complex signaling cytokine networks, adhesines,
and stromal tissue remodeling proteases (114). Cell and matrix
HS, which play a key role in orchestrating these signals, con-
tribute at all stages in the tumor growth and metastatic process
(115, 116). Most, if not all, of these molecular effectors (cytokines
and chemokines that support tumor cells progression and migra-
tion, growth factors that promote angiogenesis, matrix metalo
proteases involved in tissue degradation and remodeling, or adhe-
sion molecules such as selectin) are HS-binding proteins. HSPG
expression is developmentally regulated and altered in several
pathological situations, including cancer. In that context, the Sulf
enzymes that recently appeared to be importantly involved in the
HS remodeling that characterize both tumor cells and surround-
ing stroma, add an additional level of regulation and complexity,
and are likely to play key regulatory functions that remain to be
elucidated.
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